Personal information

No personal information available

Activities

Collapse all

Employment (3)

The University of Texas MD Anderson Cancer Center: Houston, US

2023-09 to present | Professor of Medicine (Leukemia)
Employment
Source: Self-asserted source
Naval Daver

The University of Texas MD Anderson Cancer Center: Houston, US

2017-09 to 2023-09 | Associate Professor
Employment
Source: Self-asserted source
Naval Daver

The University of Texas MD Anderson Cancer Center: Houston, US

2011-07 to 2017-08 | Assistat Professor
Employment
Source: Self-asserted source
Naval Daver

Education and qualifications (3)

Baylor College of Medicine: Houston, US

2008-07 to 2011-07 | Fellowship - Oncology-Hematology
Education
Source: Self-asserted source
Naval Daver

Baylor College of Medicine: Houston, US

2005-07 to 2008-07 | Internal Medicine Residency
Education
Source: Self-asserted source
Naval Daver

Baylor College of Medicine: Houston, US

2004-09 to 2005-06 | Research Fellowship
Education
Source: Self-asserted source
Naval Daver

Works (50 of 139)

Items per page:
Page 1 of 3

Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re‐Evaluation of Recommended Dose Adjustments With Azole Antifungals

American Journal of Hematology
2025-04 | Journal article
DOI: 10.1002/ajh.27613
Contributors: Jitesh D. Kawedia; Caitlin R. Rausch; Xiaoqian Liu; Wei Qiao; Courtney D. Dinardo; Naval Daver; Gautam Borthakur; Naveen Pemmaraju; Patrick Reville; Dimitrios P. Kontoyiannis et al.
Source: check_circle
Crossref

Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges

Cancer
2025-04 | Journal article
DOI: 10.1002/cncr.35806
Contributors: Jayastu Senapati; Tapan M. Kadia; Naval G. Daver; Courtney D. DiNardo; Gautam Borthakur; Farhad Ravandi; Hagop M. Kantarjian
Source: check_circle
Crossref

Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia

American Journal of Hematology
2025-03 | Journal article
DOI: 10.1002/ajh.27575
Contributors: Qing Wei; Shimin Hu; Sanam Loghavi; Gokce A. Toruner; Farhad Ravandi‐Kashani; Zhenya Tang; Shaoying Li; Jie Xu; Naval Daver; L. Jeffrey Medeiros et al.
Source: check_circle
Crossref

How I treat patients with AML using azacitidine and venetoclax

Blood
2025-03-20 | Journal article
DOI: 10.1182/blood.2024024009
Contributors: Andrew H. Wei; Sun Loo; Naval Daver
Source: check_circle
Crossref

A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia

Cancer
2025-03-15 | Journal article
DOI: 10.1002/cncr.35813
Contributors: Alexandre Bazinet; Alex Bataller; Tapan Kadia; Naval Daver; Nicholas J. Short; Musa Yilmaz; Koji Sasaki; Courtney D. DiNardo; Gautam M. Borthakur; Ghayas Issa et al.
Source: check_circle
Crossref

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

Leukemia
2025-02 | Journal article
DOI: 10.1038/s41375-024-02457-7
Contributors: Ian M. Bouligny; Guillermo Montalban-Bravo; Koji Sasaki; Naval Daver; Elias Jabbour; Yesid Alvarado; Courtney D. DiNardo; Farhad Ravandi; Gautam Borthakur; Naveen Pemmaraju et al.
Source: check_circle
Crossref

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

American Journal of Hematology
2025-02 | Journal article
DOI: 10.1002/ajh.27561
Contributors: Jayastu Senapati; Hagop M. Kantarjian; Fadi G. Haddad; Nicholas J. Short; Gautam Borthakur; Rashmi Kanagal‐Shamanna; Guilin Tang; Elias Jabbour; Courtney D. DiNardo; Naval Daver et al.
Source: check_circle
Crossref

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

Blood Journal
2025-02-26 | Journal article
DOI: 10.1182/blood.2024027408
Contributors: Joshua F. Zeidner; David A. Sallman; Christian Récher; Naval G. Daver; Anskar YH Leung; Devendra K. Hiwase; Marion Subklewe; Thomas Pabst; Pau Montesinos; Richard A Larson et al.
Source: check_circle
Crossref

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy

Blood Advances
2025-02-25 | Journal article
DOI: 10.1182/bloodadvances.2024013826
Contributors: Wei-Ying Jen; Koji Sasaki; Farhad Ravandi; Tapan M. Kadia; Sa A. Wang; Wei Wang; Sanam Loghavi; Naval G. Daver; Courtney D. DiNardo; Ghayas C. Issa et al.
Source: check_circle
Crossref

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Leukemia
2025-02-25 | Journal article
DOI: 10.1038/s41375-025-02531-8
Contributors: Courtney D. DiNardo; Wei-Ying Jen; Koichi Takahashi; Tapan M. Kadia; Sanam Loghavi; Naval G. Daver; Lianchun Xiao; Patrick K. Reville; Ghayas C. Issa; Nicholas J. Short et al.
Source: check_circle
Crossref

Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies

American Journal of Hematology
2025-02-08 | Journal article
DOI: 10.1002/ajh.27628
Contributors: Jayastu Senapati; Sanam Loghavi; Jennifer Marvin‐Peek; Guillermo Garcia‐Manero; Tapan M. Kadia; Gautam Borthakur; Naval Daver; Nicholas J. Short; Nitin Jain; Ghayas C. Issa et al.
Source: check_circle
Crossref

Acute myeloid leukemia management and research in 2025

CA: A Cancer Journal for Clinicians
2025-01 | Journal article
DOI: 10.3322/caac.21873
Contributors: Hagop M. Kantarjian; Courtney D. DiNardo; Tapan M. Kadia; Naval G. Daver; Jessica K. Altman; Eytan M. Stein; Elias Jabbour; Charles A. Schiffer; Amy Lang; Farhad Ravandi
Source: check_circle
Crossref

Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia

Cancer
2025-01 | Journal article
DOI: 10.1002/cncr.35662
Contributors: Wei‐Ying Jen; Jennifer Marvin‐Peek; Hagop M. Kantarjian; Yesid Alvarado; Gautam Borthakur; Elias Jabbour; William Wierda; Tapan M. Kadia; Naval G. Daver; Courtney D. DiNardo et al.
Source: check_circle
Crossref

TP53 Mutant Variant Allele Frequency and Cytogenetics Determine Prognostic Groups in MDS/AML for Transplantation

Blood Advances
2025-01-24 | Journal article
DOI: 10.1182/bloodadvances.2024014499
Contributors: Konstantinos Lontos; Rima M Saliba; Rashmi Kanagal-Shamanna; Gonca Ozcan; Jeremy Leon Ramdial; George Liwei Chen; Tapan M. Kadia; Nicholas J Short; Naval G. Daver; Hagop M. Kantarjian et al.
Source: check_circle
Crossref

Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia

Blood Cancer Discovery
2025-01-08 | Journal article
DOI: 10.1158/2643-3230.BCD-24-0171
Contributors: Hannah Goulart; Hagop Kantarjian; Naveen Pemmaraju; Naval Daver; Courtney D. DiNardo; Caitlin R. Rausch; Farhad Ravandi; Tapan M. Kadia
Source: check_circle
Crossref

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL

Journal of Clinical Oncology
2024-12-20 | Journal article
DOI: 10.1200/JCO.24.00272
Contributors: Hagop Kantarjian; Nicholas J. Short; Fadi G. Haddad; Nitin Jain; Xuelin Huang; Guillermo Montalban-Bravo; Rashmi Kanagal-Shamanna; Tapan M. Kadia; Naval Daver; Kelly Chien et al.
Source: check_circle
Crossref

A phase 2 trial of mini‐hyper‐CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia

American Journal of Hematology
2024-11 | Journal article
DOI: 10.1002/ajh.27463
Contributors: Wei‐Ying Jen; Elias Jabbour; Nicholas J. Short; Ghayas C. Issa; Fadi G. Haddad; Nitin Jain; Naveen Pemmaraju; Naval G. Daver; Lucia Masarova; Gautam Borthakur et al.
Source: check_circle
Crossref

What have we learned about TP53-mutated acute myeloid leukemia?

Blood Cancer Journal
2024-11-19 | Journal article
DOI: 10.1038/s41408-024-01186-5
Contributors: Moazzam Shahzad; Muhammad Kashif Amin; Naval G. Daver; Mithun Vinod Shah; Devendra Hiwase; Daniel A. Arber; Mohamed A. Kharfan-Dabaja; Talha Badar
Source: check_circle
Crossref

Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation

Cancer
2024-10 | Journal article
DOI: 10.1002/cncr.35388
Contributors: Jayastu Senapati; Hagop M. Kantarjian; Alexandre Bazinet; Patrick Reville; Nicholas J. Short; Naval Daver; Gautam Borthakur; Alex Bataller; Elias Jabbour; Courtney DiNardo et al.
Source: check_circle
Crossref

Current status and research directions in acute myeloid leukemia

Blood Cancer Journal
2024-09-19 | Journal article
DOI: 10.1038/s41408-024-01143-2
Contributors: Hagop Kantarjian; Gautam Borthakur; Naval Daver; Courtney D. DiNardo; Ghayas Issa; Elias Jabbour; Tapan Kadia; Koji Sasaki; Nicholas J. Short; Musa Yilmaz et al.
Source: check_circle
Crossref

Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia

Cancer
2024-08 | Journal article
DOI: 10.1002/cncr.35317
Contributors: Elias Jabbour; Fadi G. Haddad; Koji Sasaki; Bing Z. Carter; Yesid Alvarado; Cedric Nasnas; Lewis Nasr; Lucia Masarova; Naval Daver; Naveen Pemmaraju et al.
Source: check_circle
Crossref

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease

British Journal of Haematology
2024-07 | Journal article
DOI: 10.1111/bjh.19519
Contributors: Wei‐Ying Jen; Hagop Kantarjian; Tapan M. Kadia; Courtney D. DiNardo; Ghayas C. Issa; Nicholas J. Short; Musa Yilmaz; Gautam Borthakur; Farhad Ravandi; Naval G. Daver
Source: check_circle
Crossref

Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML

Blood Neoplasia
2024-06 | Journal article
DOI: 10.1016/j.bneo.2024.100008
Contributors: Samuel Urrutia; Prithviraj Bose; Yesid Alvarado; Gautam Borthakur; Farhad Ravandi; Naval Daver; Naveen Pemmaraju; Elias Jabbour; Koichi Takahashi; Tapan Kadia et al.
Source: check_circle
Crossref

Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome

Journal of Clinical Oncology
2024-05-20 | Journal article
DOI: 10.1200/JCO.24.00006
Contributors: Naval G. Daver; Charles Craddock
Source: check_circle
Crossref

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology
2024-05-01 | Journal article
DOI: 10.1200/JCO.23.01911
Contributors: Nicholas J. Short; Naval Daver; Courtney D. Dinardo; Tapan Kadia; Lewis F. Nasr; Walid Macaron; Musa Yilmaz; Gautam Borthakur; Guillermo Montalban-Bravo; Guillermo Garcia-Manero et al.
Source: check_circle
Crossref

Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups

American Journal of Hematology
2024-04 | Journal article
DOI: 10.1002/ajh.27236
Contributors: Alex Bataller; Courtney D. DiNardo; Alexandre Bazinet; Naval G. Daver; Abhishek Maiti; Gautam Borthakur; Nicholas Short; Koji Sasaki; Elias J. Jabbour; Ghayas C. Issa et al.
Source: check_circle
Crossref

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Leukemia
2024-03 | Journal article
DOI: 10.1038/s41375-023-02108-3
Contributors: Christine E. Birdwell; Warren Fiskus; Tapan M. Kadia; Christopher P. Mill; Koji Sasaki; Naval Daver; Courtney D. DiNardo; Naveen Pemmaraju; Gautam Borthakur; John A. Davis et al.
Source: check_circle
Crossref

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Blood Advances
2024-02-27 | Journal article
DOI: 10.1182/bloodadvances.2023011757
Contributors: Alex Bataller; Alexandre Bazinet; Courtney D. DiNardo; Abhishek Maiti; Gautam Borthakur; Naval G. Daver; Nicholas J. Short; Elias J. Jabbour; Ghayas C. Issa; Naveen Pemmaraju et al.
Source: check_circle
Crossref

Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

American Journal of Hematology
2023-11 | Journal article
DOI: 10.1002/ajh.27054
Contributors: Tapan M. Kadia; Farhad Ravandi; Matteo Molica; Alex Bataller; Gautam Borthakur; Naval Daver; Elias Jabbour; Courtney D. DiNardo; Naveen Pemmaraju; Nitin Jain et al.
Source: check_circle
Crossref

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood
2023-11-09 | Journal article
DOI: 10.1182/blood.2023020649
Contributors: Jayastu Senapati; Samuel Urrutia; Sanam Loghavi; Nicholas J. Short; Ghayas C. Issa; Abhishek Maiti; Hussein A. Abbas; Naval G. Daver; Naveen Pemmaraju; Sherry Pierce et al.
Source: check_circle
Crossref

Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.24473460
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.24473460.v1
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Data from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.c.6908253
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Data from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.c.6908253.v1
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research
2023-11-01 | Journal article
DOI: 10.1158/1078-0432.CCR-23-1429
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.24473457
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.24473457.v1
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.24473454
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

2023-11-01 | Preprint
DOI: 10.1158/1078-0432.24473454.v1
Contributors: Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger et al.
Source: check_circle
Crossref

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Journal of Clinical Oncology
2023-11-01 | Journal article
DOI: 10.1200/JCO.22.02604
Contributors: Naval G. Daver; Paresh Vyas; Suman Kambhampati; Monzr M. Al Malki; Richard A. Larson; Adam S. Asch; Gabriel Mannis; Wanxing Chai-Ho; Tiffany N. Tanaka; Terrence J. Bradley et al.
Source: check_circle
Crossref

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology
2023-09 | Journal article
DOI: 10.1002/ajh.26997
Contributors: Alexandre Bazinet; Hagop Kantarjian; Naszrin Arani; Uday Popat; Alex Bataller; Koji Sasaki; Courtney D. DiNardo; Naval Daver; Musa Yilmaz; Hussein A. Abbas et al.
Source: check_circle
Crossref

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Blood Cancer Journal
2023-09-21 | Journal article
DOI: 10.1038/s41408-023-00915-6
Contributors: Danielle Hammond; Sanam Loghavi; Sa A. Wang; Marina Y. Konopleva; Tapan M. Kadia; Naval G. Daver; Maro Ohanian; Ghayas C. Issa; Yesid Alvarado; Nicholas J. Short et al.
Source: check_circle
Crossref

The role of therapy in the outcome of patients with myelofibrosis

Cancer
2023-09-15 | Journal article
DOI: 10.1002/cncr.34851
Contributors: Lucia Masarova; Prithviraj Bose; Naveen Pemmaraju; Naval G. Daver; Koji Sasaki; Helen T. Chifotides; Lingsha Zhou; Hagop M. Kantarjian; Zeev Estrov; Srdan Verstovsek
Source: check_circle
Crossref

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion

American Journal of Hematology
2023-08 | Journal article
DOI: 10.1002/ajh.26941
Contributors: Naval G. Daver; Shahed Iqbal; Julie Huang; Camille Renard; Joyce Lin; Yang Pan; Mellissa Williamson; Giridharan Ramsingh
Source: check_circle
Crossref

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Advances
2023-07-25 | Journal article
DOI: 10.1182/bloodadvances.2022009632
Contributors: Nicholas J. Short; Faustine Ong; Farhad Ravandi; Graciela Nogueras-Gonzalez; Tapan M. Kadia; Naval Daver; Courtney D. DiNardo; Marina Konopleva; Gautam Borthakur; Betul Oran et al.
Source: check_circle
Crossref

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Leukemia
2023-06 | Journal article
DOI: 10.1038/s41375-023-01882-4
Contributors: Christopher P. Mill; Warren Fiskus; Kaberi Das; John A. Davis; Christine E. Birdwell; Tapan M. Kadia; Courtney D. DiNardo; Naval Daver; Koichi Takahashi; Koji Sasaki et al.
Source: check_circle
Crossref

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer
2023-06-15 | Journal article
DOI: 10.1002/cncr.34728
Contributors: Daniel Nguyen; Hagop M. Kantarjian; Nicholas J. Short; Wei Qiao; Jing Ning; Branko Cuglievan; Naval G. Daver; Courtney D. DiNardo; Elias J. Jabbour; Tapan M. Kadia et al.
Source: check_circle
Crossref

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements

JCO Precision Oncology
2023-05 | Journal article
DOI: 10.1200/PO.22.00707
Contributors: Jayastu Senapati; Elias Jabbour; Marina Konopleva; Nicholas J. Short; Guilin Tang; Naval Daver; Partow Kebriaei; Tapan Kadia; Naveen Pemmaraju; Koichi Takahashi et al.
Source: check_circle
Crossref

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Blood Advances
2023-05-23 | Journal article
DOI: 10.1182/bloodadvances.2022008790
Contributors: Nitin Jain; Jayastu Senapati; Beenu Thakral; Alessandra Ferrajoli; Philip Thompson; Jan Burger; Sreyashi Basu; Tapan Kadia; Naval Daver; Gautam Borthakur et al.
Source: check_circle
Crossref

Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements

American Journal of Hematology
2023-04 | Journal article
DOI: 10.1002/ajh.26858
Contributors: Maria Siddiqui; Sergej Konoplev; Ghayas Issa; Hagop Kantarjian; Naval Daver; Farhad Ravandi; Tapan Kadia; Guilin Tang; Sa A. Wang; Beenu Thakral et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 3

Peer review (30 reviews for 6 publications/grants)

Review activity for Blood cancer journal. (21)
Review activity for Journal of hematology & oncology. (4)
Review activity for Leukemia (2)
Review activity for Nature cancer. (1)
Review activity for Nature communications (1)
Review activity for Nature medicine. (1)
How many people are using ORCID?